Analytical Data
-
Gene name
GPIHBP1
- Application
-
Alternative Names
GPI-HBP1; High density lipoprotein-binding protein 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q8IV16
-
Expression Region
Gln21~Gly151
-
Molecular Weight
21kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GPIHBP1, or Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1, plays a critical role in lipid metabolism, particularly in the transport of triglyceride-rich lipoproteins. Research has indicated that GPIHBP1 functions as a bridge between lipoprotein lipase (LPL) and circulating triglyceride-rich lipoproteins, facilitating the hydrolysis of triglycerides in the bloodstream. Mutations in the GPIHBP1 gene have been linked to chylomicronemia syndrome, a rare disorder characterized by impaired lipid metabolism and significantly elevated triglyceride levels. These findings have underscored the importance of GPIHBP1 as a key player in lipid homeostasis and the regulation of cardiovascular health. The recombinant protein derived from GPIHBP1 has been the focus of numerous studies, aiming to better understand its structure-function relationship and potential therapeutic applications. By elucidating the mechanisms by which GPIHBP1 interacts with LPL and lipoproteins, researchers hope to develop targeted strategies for treating dyslipidemias and related cardiovascular diseases. The ongoing investigation into GPIHBP1 not only enhances our comprehension of lipid metabolism but also paves the way for novel interventions that could mitigate the risk of lipid-related disorders.
